Clinical Trials Browser

Phase 2 × olaparib × Gastrointestinal × Clear all

NCT04548752 2026-03-18

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03212274 2026-02-19

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Phase 2 Active not recruiting

CNSGastrointestinal

Glioblastoma, Glioma, Cholangiocarcinoma

NCT03155620 2026-02-10

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase 2 Active not recruiting

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04753879 2025-12-04

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04209686 2025-12-03

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT03878095 2025-11-17

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT05093231 2025-09-18

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Phase 2 Completed

298 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Ovarian

NCT06441747 2025-07-29

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT05379972 2025-07-16

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT04306367 2025-02-17

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

Phase 2 Completed

14 enrolled 13 charts

Gastrointestinal

Cholangiocarcinoma

NCT05222971 2025-01-28

OPTIMUM

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT03233204 2024-12-11

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Phase 2 Completed

6 enrolled 12 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT02677038 2024-10-01

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Phase 2 Completed

24 enrolled 8 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT03991832 2024-07-18

SOLID

Phase 2 Recruiting

CNSGastrointestinal

Glioma, Cholangiocarcinoma

NCT06078787 2024-05-06

PALBOLA

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03579784 2024-04-19

Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Advanced Gastric Cancer

NCT04298021 2024-04-19

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

Phase 2 Active not recruiting

Gastrointestinal

Bile Duct Neoplasms

NCT04166435 2023-09-06

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

Phase 2 Completed

11 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT01063517 2023-07-20

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

Phase 2 Completed

124 enrolled 27 charts

Gastrointestinal

Stomach Neoplasms

NCT05411679 2023-06-12

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Phase 2 Withdrawn

GastrointestinalThoracic

Stomach Neoplasms, Small Cell Lung Carcinoma

NCT02511223 2023-04-19

10

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT05201612 2023-02-24

PEMBROLA

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT03829345 2019-07-08

SOLAR

Phase 2 Unknown

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT00912743 2016-11-09

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Phase 2 Completed

33 enrolled 9 charts

Gastrointestinal

Colorectal Neoplasms